Mirikizumab
Mirikizumab
Mirikizumab (pronunciation: mi-ri-ki-zu-mab) is a monoclonal antibody designed for the treatment of immune-mediated inflammatory diseases.
Etymology
The name "Mirikizumab" is derived from the Greek words "miri" meaning myriad and "kizumab" which is a common suffix for monoclonal antibodies.
Description
Mirikizumab is a humanized monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23), a cytokine that plays a key role in autoimmune diseases. By blocking the action of IL-23, mirikizumab can reduce inflammation and help manage symptoms of diseases like psoriasis, Crohn's disease, and ulcerative colitis.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Interleukin 23 (IL-23): A cytokine that plays a key role in managing the immune system and inflammation.
- Psoriasis: A chronic skin condition caused by an overactive immune system.
- Crohn's Disease: A type of inflammatory bowel disease (IBD) that may affect any part of the gastrointestinal tract from mouth to anus.
- Ulcerative Colitis: A chronic, inflammatory bowel disease that causes inflammation in the digestive tract.
See Also
- Monoclonal Antibodies in Immunotherapy
- Cytokines
- Inflammatory Bowel Disease (IBD)
- Autoimmune Diseases
External links
- Medical encyclopedia article on Mirikizumab
- Wikipedia's article - Mirikizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski